Cargando…

Antidepressants as Autophagy Modulators for Cancer Therapy

Cancer is a major global public health problem with high morbidity. Depression is known to be a high-frequency complication of cancer diseases that decreases patients’ life quality and increases the mortality rate. Therefore, antidepressants are often used as a complementary treatment during cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Leping, Fu, Yuanfeng, Tian, Yuxi, Wang, Xiaofeng, Zhou, Xuejun, Ding, Ren-Bo, Qi, Xingzhu, Bao, Jiaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673223/
https://www.ncbi.nlm.nih.gov/pubmed/38005316
http://dx.doi.org/10.3390/molecules28227594
_version_ 1785149589465071616
author He, Leping
Fu, Yuanfeng
Tian, Yuxi
Wang, Xiaofeng
Zhou, Xuejun
Ding, Ren-Bo
Qi, Xingzhu
Bao, Jiaolin
author_facet He, Leping
Fu, Yuanfeng
Tian, Yuxi
Wang, Xiaofeng
Zhou, Xuejun
Ding, Ren-Bo
Qi, Xingzhu
Bao, Jiaolin
author_sort He, Leping
collection PubMed
description Cancer is a major global public health problem with high morbidity. Depression is known to be a high-frequency complication of cancer diseases that decreases patients’ life quality and increases the mortality rate. Therefore, antidepressants are often used as a complementary treatment during cancer therapy. During recent decades, various studies have shown that the combination of antidepressants and anticancer drugs increases treatment efficiency. In recent years, further emerging evidence has suggested that the modulation of autophagy serves as one of the primary anticancer mechanisms for antidepressants to suppress tumor growth. In this review, we introduce the anticancer potential of antidepressants, including tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). In particular, we focus on their autophagy-modulating mechanisms for regulating autophagosome formation and lysosomal degradation. We also discuss the prospect of repurposing antidepressants as anticancer agents. It is promising to repurpose antidepressants for cancer therapy in the future.
format Online
Article
Text
id pubmed-10673223
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106732232023-11-14 Antidepressants as Autophagy Modulators for Cancer Therapy He, Leping Fu, Yuanfeng Tian, Yuxi Wang, Xiaofeng Zhou, Xuejun Ding, Ren-Bo Qi, Xingzhu Bao, Jiaolin Molecules Review Cancer is a major global public health problem with high morbidity. Depression is known to be a high-frequency complication of cancer diseases that decreases patients’ life quality and increases the mortality rate. Therefore, antidepressants are often used as a complementary treatment during cancer therapy. During recent decades, various studies have shown that the combination of antidepressants and anticancer drugs increases treatment efficiency. In recent years, further emerging evidence has suggested that the modulation of autophagy serves as one of the primary anticancer mechanisms for antidepressants to suppress tumor growth. In this review, we introduce the anticancer potential of antidepressants, including tricyclic antidepressants (TCAs), tetracyclic antidepressants (TeCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs). In particular, we focus on their autophagy-modulating mechanisms for regulating autophagosome formation and lysosomal degradation. We also discuss the prospect of repurposing antidepressants as anticancer agents. It is promising to repurpose antidepressants for cancer therapy in the future. MDPI 2023-11-14 /pmc/articles/PMC10673223/ /pubmed/38005316 http://dx.doi.org/10.3390/molecules28227594 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
He, Leping
Fu, Yuanfeng
Tian, Yuxi
Wang, Xiaofeng
Zhou, Xuejun
Ding, Ren-Bo
Qi, Xingzhu
Bao, Jiaolin
Antidepressants as Autophagy Modulators for Cancer Therapy
title Antidepressants as Autophagy Modulators for Cancer Therapy
title_full Antidepressants as Autophagy Modulators for Cancer Therapy
title_fullStr Antidepressants as Autophagy Modulators for Cancer Therapy
title_full_unstemmed Antidepressants as Autophagy Modulators for Cancer Therapy
title_short Antidepressants as Autophagy Modulators for Cancer Therapy
title_sort antidepressants as autophagy modulators for cancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673223/
https://www.ncbi.nlm.nih.gov/pubmed/38005316
http://dx.doi.org/10.3390/molecules28227594
work_keys_str_mv AT heleping antidepressantsasautophagymodulatorsforcancertherapy
AT fuyuanfeng antidepressantsasautophagymodulatorsforcancertherapy
AT tianyuxi antidepressantsasautophagymodulatorsforcancertherapy
AT wangxiaofeng antidepressantsasautophagymodulatorsforcancertherapy
AT zhouxuejun antidepressantsasautophagymodulatorsforcancertherapy
AT dingrenbo antidepressantsasautophagymodulatorsforcancertherapy
AT qixingzhu antidepressantsasautophagymodulatorsforcancertherapy
AT baojiaolin antidepressantsasautophagymodulatorsforcancertherapy